Ocular Hyperemia

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Ocular Hyperemia trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 4

NCT07209410

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro…

To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for in…

United States35 participantsStarted 2025-11-01

Treatment: Brimonidine Tartrate Ophthalmic 0.025%

All recent trials (21 shown)

Not Yet RecruitingPhase 3

NCT07531043

An Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness

The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irrita…

United States240 participantsStarted 2026-10

Treatment: Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle

CompletedNot Applicable

NCT07521293

Intracranial Pressure and a Potential Vicious Circle of Atrial Fibrillation in HFpEF

This study was designed to investigate predictors of atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF), with a pa…

Turkey (Türkiye)309 participantsStarted 2025-10-14

Treatment: Echocardiography

Ocular Hyperemia

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro…

All recent trials (21 shown)

An Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness

Intracranial Pressure and a Potential Vicious Circle of Atrial Fibrillation in HFpEF

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro…

All recent trials (21 shown)

An Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness

Intracranial Pressure and a Potential Vicious Circle of Atrial Fibrillation in HFpEF

Safety and Tolerability of PRO-185

Manifestations of Ocular Irritation Following Pterygium Excision With Sutures Fixed Conjunctival Autograft

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia

Validation of an Artificial Intelligence System for Postoperative Management of Cataract Patients

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost

A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma

Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Succe…

Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Trav…

Results of Mass Switch From Latanoprost to Travoprost

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hyper…